304 related articles for article (PubMed ID: 3282579)
21. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Looby M; Linke R; Weiss M
Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetics and action mechanism of anthracyclines].
Fukushima T; Ueda T; Nakamura T
Gan To Kagaku Ryoho; 1992 Apr; 19(4):445-50. PubMed ID: 1558393
[TBL] [Abstract][Full Text] [Related]
25. [New anthracyclines in the treatment of solid tumors in the advanced stage].
Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
[No Abstract] [Full Text] [Related]
26. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
Gallois L; Fiallo M; Garnier-Suillerot A
Biochim Biophys Acta; 1998 Mar; 1370(1):31-40. PubMed ID: 9518541
[TBL] [Abstract][Full Text] [Related]
27. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
Cini-Neri G; Neri B
Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
29. [Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation].
Shinozawa S; Gomita Y; Araki Y
Gan To Kagaku Ryoho; 1992 Jun; 19(6):805-9. PubMed ID: 1605657
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
Maniez-Devos DM; Baurain R; Lesne M; Trouet A
J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
[TBL] [Abstract][Full Text] [Related]
31. [Current status of clinical results of new antitumor drugs].
Ogawa M
Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
[TBL] [Abstract][Full Text] [Related]
32. Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture.
Kyle AH; Huxham LA; Chiam AS; Sim DH; Minchinton AI
Cancer Res; 2004 Sep; 64(17):6304-9. PubMed ID: 15342419
[TBL] [Abstract][Full Text] [Related]
33. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
34. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
[TBL] [Abstract][Full Text] [Related]
35. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
[TBL] [Abstract][Full Text] [Related]
36. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R
J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924
[TBL] [Abstract][Full Text] [Related]
37. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
38. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
39. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
40. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]